Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors

US7906533B2 · kind B2 · utility

Assignee

• Bayer Schering Pharma AG · DE

Inventors

• Rolf Bohlmann · Berlin, DE
• Martin Haberey · Berlin, DE
• Andreas Huth · Berlin, DE
• Stuart Ince · Berlin, DE
• Martin Krueger · Berlin, DE
• Karl-Heinz Thierauch · Berlin, DE
• Holger Hess-Stumpp · Berlin, DE

Key dates

• Filing date: Nov 1, 2005
• Grant date: Mar 15, 2011
• Expiry date: Mar 18, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.